One of the major successes of Hamied was building a strong US business, despite Cipla being a late entrant. Hamied said this was possible by pursuing selective yet complex generic portfolios. Cipla entered the US market in a big way with the strategic acquisitions of two generic companies, InvaGen Pharma and Exelan Pharma, for $550 million in 2015.
Drugmaker CIPLA wants to be more than just a pharmaceutical company selling a pill and aims to play a bigger role in a patient’s journey from illness to wellness. Samina Hamied, executive vicechairperson who won the ET Businesswoman of the Year 2021, in an interview with ET said that in the post-Covid world, Cipla wants to handhold patients right from testing, treatment adherence, building awareness, wellness and accessibility to medicines
